ADVANTAGES, SAFETY AND PROSPECTS OF SITAGLIPTIN APPLICATION IN TYPE 2 DIABETES MELLITUS WITH CHRONIC KIDNEY DISEASE
https://doi.org/10.21518/2079-701X-2017-11-170-175
Abstract
The incidence of chronic kidney disease (CKD) in Type 2 Diabetes Mellitus patients accounts for 34,6–40% of cases. The importance of glycemic control for the prevention of kidney damage and progression of nephropathy in T2DM patients is proven in numerous studies. The presence of CKD significantly limits the choice of antidiabetic drugs and requires changes in dosages. Sitagliptin-DPP-4 inhibitor is approved for use at any stage of CKD. Clinical studies involving Sitagliptin provide a powerful base demonstrating the effectiveness and safety of the drug in CKD. The article presents the data of clinical and experimental studies indicating the protective role of Sitagliptin in the development of renal damage. The animal experiments revealed that the suppression of the activity of DPP-4 by Sitagliptin in kidneys leads to regression of renal damage, with reduced markers of inflammation and endothelial dysfunction.
About the Author
I. A. Bonda
Novosibirsk State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, Prof.
References
1. IDF Diabetes Atlas. 6th Edition. Available from: http://www.idf.org/diabetesatlas.
2. Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2015 г. и перспективы развития. Сахарный диабет, 2015, 18(3): 5-22.
3. Сунцов Ю.И., Болотская Л.Л., Маслова О.В., и др. Эпидемиология сахарного диабета и прогноз его распространенности в Российской Федерации. Сахарный диабет, 2011, 14(1): 15-19.
4. Шестакова М.В., Чазова И.Е., Шестакова Е.А. Российское многоцентровое скрининговое исследование по выявлению недиагностированного сахарного диабета 2 типа у пациентов с сердечно-сосудистой патологией. Сахарный диабет, 2016, 19(1): 24-29.
5. Дедов И.И., Омельяновский В.В., Шестакова М.В., Арсентьева М.В., Игнатьева В.И. Cахарный диабет как экономическая проблема в Российской Федерации. Сахарный диабет, 2016, 19(1): 30-43.
6. Iglesias P., Heras M., Diez J.J. Diabetes mellitus and kidney disease in the elderly. Nefrologia, 2014, 34(3): 285-92.
7. Маслова О.В., Сунцов Ю.И., Шестакова М.В. и соавт. Распространенность поражения почек при сахарном диабете 1 и 2 типов в Российской Федерации. Сахарный диабет, 2009, 12(4): 48-51.
8. Кобалава Ж.Д., Виллевальде С.В., Ефремцева М.А. Основы кардиоренальной медицины. М.: ГЭОТАР-Медиа, 2014. 254 c.
9. Astor BC, Hallan SI, Miller ER et al. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol, 2008, 167: 1226-1234.
10. Бондарь И.А., Зенкова Е.В., Краснопевцева И.П., Шабельникова О.Ю. Хроническая болезнь почек при сахарном диабете 2 типа: частота, причины развития, особенности сахароснижающей терапии. Сибирский научный медицинский журнал, 2017, 37(1): 81-87.
11. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med, 2008, 358(6): 580-591.
12. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008, 358(24): 2560-2572.
13. Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S et al. Alberta Kidney Disease Network. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronickidney disease: a population-based cohort study. Arch Intern Med, 2011, 171(21):1920-1927.
14. Drechsler C, Krane V, Ritz E, Mдrz W, Wanner C. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation, 2009, 120(24): 2421-2428.
15. Шамхалова М.Ш., Ярек-Мартынова И.Я., Трубицына Н.П., Шестакова М.В. Особенности сахароснижающей терапии у больных сахарным диабетом и хронической болезнью почек. Сахарный диабет, 2013, 16(3): 97-102.
16. Сахарный диабет: диагностика, лечение, профилактика /Под ред. И.И.Дедова, М.В.Шестаковой. М.: ООО «Издательство «Медицинское информационное агенство», 2011. 808 c.
17. Мкртумян А.М., Подачина С.В., Свиридова М.А., Канаузов М.Я. Результаты и перспективы применения ингибитора ДПП-4 у больных сахарным диабетом 2-го типа. Медицинский совет, 2013, 3-2: 104-110.
18. Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Sci (Lond), 2013, 124(1): 17-26.
19. Tatosian DA, Guo Y, Schaeffer AK et al. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther, 2013, 4: 431-442.
20. Анциферов М.Б., Schernthaner G., Аметов А.С. Инновационная сахароснижающая терапия: новая стратегия для старой проблемы. Фарматека, 2013, 5: 37-47.
21. Власов Т.Д., Симаненкова А.В., Дора С.В., Шляхто Е.В., Механизмы нейропротективного действия инкретиномиметиков. Сахарный диабет, 2016, 19(1): 16-23.
22. Аметов А.С., Камынина Л.А. Негликемические эффекты ингибиторов дипептидилпептидазы. Терапевтический архив, 2013, 1: 98-102.
23. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism, 2014, 63(9): 1141-1148.
24. Mega C, Teixeira de Lemos E, Vala H et al. Diabetic nephropathy amelioration by a lowdose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res, 2011, 2011: 1-12.
25. Marques C, Mega C, Gonçalves A et al. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators Inflamm, 2014, 2014: 1-15.
26. Nuransoy A, Beytur A, Polat A et al. Protective effect of sitagliptin against renal ischemia reperfusion injury in rats. Ren Fail, 2015, 37(4): 687-693.
27. Chang MW, Chen CH, Chen YC et al. Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors. Acta Pharmacol Sin, 2015, 36(1): 119-130.
28. Matsui T., Nakashima S., Nishino Y., et al. Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis. Lab Investig, 2015, 95(5): 525-533.
29. Liu L, Liu J, Wong WT et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagonlike peptide 1-dependent mechanism. Hypertension, 2012, 60(3): 833-841.
30. Januvia (sitagliptin) prescribing information. Whitehouse Station, NJ, Merck & Co., Inc, 2009.
31. Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care, 2007, 30(7): 1862-1864.
32. Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Devies MJ et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab, 2008, 10(7): 545-555.
33. Odegaard D, Lane J, Haire C. Sitagliptin use in kidney transplant recipients: Effect on immunosuppressant levels. Diabetes, 2008, 58(Suppl. 1): A646.
34. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J, 2011, 58(1): 69-73.
35. Mori H, Okada Y, Arao T, Tanaka Y. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Investig, 2014, 5(3): 313-319.
36. Kawasaki I, Hiura Y, Tamai A et al. Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate. J Diabetes, 2015, 7(1): 41-46.
37. Zheng T, Baskota A, Gao Y et al. Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in Chinese without diabetes: a four-year prospective study. Nephrol Dial Transplant, 2015, 30 (3): 460-466.
38. Bethel MA, Green JB, Milton J et al. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metab, 2015, 17(4): 395-402.
39. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2015, 373(3): 232-42.
40. Аметов А.С., Камынина Л.Л. TECOS – новое исследование по оценке сердечно-сосудистой безопасности ингибитора дипептидилпептидазы-4 ситаглиптина. Эндокринология: новости, мнения, обучение, 2015, 3: 38-50.
41. Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS. Diabetes Care, 2016, 39(12): 2304-2310.
Review
For citations:
Bonda IA. ADVANTAGES, SAFETY AND PROSPECTS OF SITAGLIPTIN APPLICATION IN TYPE 2 DIABETES MELLITUS WITH CHRONIC KIDNEY DISEASE. Meditsinskiy sovet = Medical Council. 2017;(11):170-175. (In Russ.) https://doi.org/10.21518/2079-701X-2017-11-170-175
Views:
773
Email this article 